Finding ways to reduce harmful cells in lung fibrosis
Reducing Fibroblast Persistence in Pulmonary Fibrosis as a Mechanism of Resolution
['FUNDING_R01'] · NATIONAL JEWISH HEALTH · NIH-10661572
This study is looking at how certain cells in the lungs that don't die off as they should can make lung fibrosis worse, and it aims to find new ways to help improve breathing for people with this condition by focusing on a specific gene that keeps these cells alive.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NATIONAL JEWISH HEALTH (nih funded) |
| Locations | 1 site (DENVER, UNITED STATES) |
| Trial ID | NIH-10661572 on ClinicalTrials.gov |
What this research studies
This research investigates how certain cells called pro-fibrotic fibroblasts contribute to lung fibrosis, a serious condition that affects breathing. The study focuses on understanding why these cells persist and do not die off as they should, which leads to worsening lung function. By exploring the role of a specific gene, Bcl-2, in preventing the death of these cells, the research aims to identify new therapeutic targets that could help reverse or slow down the progression of pulmonary fibrosis. Patients may benefit from potential new treatments that could improve their lung health and quality of life.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pulmonary fibrosis or interstitial lung diseases, particularly those with a history of exposure to harmful substances like silica dust or cigarette smoke.
Not a fit: Patients with pulmonary fibrosis caused by genetic factors or those who are not responsive to current treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively reduce lung fibrosis and improve breathing for patients.
How similar studies have performed: Previous research has shown promise in targeting fibroblast activity in lung diseases, suggesting that this approach could lead to meaningful advancements in treatment.
Where this research is happening
DENVER, UNITED STATES
- NATIONAL JEWISH HEALTH — DENVER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: REDENTE, ELIZABETH FRANCES — NATIONAL JEWISH HEALTH
- Study coordinator: REDENTE, ELIZABETH FRANCES
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.